金河生物(002688) - 2024 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2024 was CNY 519,450,050.36, a decrease of 1.49% compared to CNY 527,286,393.92 in the same period last year[4] - Net profit attributable to shareholders increased by 22.27% to CNY 45,143,153.81 from CNY 36,920,074.20 year-on-year[4] - Basic and diluted earnings per share rose by 22.20% to CNY 0.0578 from CNY 0.0473 in the same quarter last year[4] - Net profit for the current period is ¥47,574,039.07, an increase of 17.5% compared to ¥40,439,624.37 in the previous period[31] - Operating profit increased to ¥49,988,476.89 from ¥43,377,486.42, reflecting a growth of 15.5%[31] Cash Flow - Net cash flow from operating activities surged by 443.71% to CNY 73,390,050.46, compared to a negative cash flow of CNY 21,352,026.70 in the previous year[4] - The net cash flow from operating activities increased by ¥94,742,077.16, a growth of 443.71%, mainly due to improved collection of receivables and tax refunds including those from Farmawei[13] - Cash flow from operating activities generated a net amount of ¥73,390,050.46, a significant improvement from a net outflow of ¥21,352,026.70 in the previous period[32] - The company experienced a net increase in cash flow from financing activities of ¥110,615,175.28, compared to ¥80,682,022.28 in the previous period, an increase of 37.0%[33] Assets and Liabilities - Total assets increased by 2.49% to CNY 5,589,499,836.96 from CNY 5,453,807,416.04 at the end of the previous year[4] - The company's total liabilities increased to RMB 3,060,290,865.82 from RMB 2,937,125,973.28, representing a rise of approximately 4.2%[28] - The company's equity attributable to shareholders rose to RMB 2,257,006,117.23 from RMB 2,246,791,261.75, showing a slight increase of about 0.5%[28] Investments and Expenses - Interest expenses increased by 49.81% to CNY 18,748,659.76, attributed to higher bank borrowing and capitalized interest being expensed[7] - The company reported a net loss from investment of CNY 484,445.19 due to the cancellation of an overseas subsidiary[7] - Research and development expenses increased to ¥19,538,556.28 from ¥15,311,156.03, showing a growth of 27.5%[29] Comprehensive Income - Comprehensive income increased by 35.24% to CNY 46,000,695.56, driven by lower raw material prices and favorable exchange rate effects[12] - The company reported a total comprehensive income of ¥46,785,956.65, up from ¥34,595,261.09, reflecting a growth of 35.2%[32] Share Repurchase - The company repurchased a total of 12,653,800 shares, accounting for 1.62% of the total share capital, with a total transaction amount of RMB 38,743,685.21[22] - The highest transaction price during the repurchase was RMB 3.27 per share, while the lowest was RMB 2.92 per share[22] - The company plans to use the repurchased shares for employee stock ownership plans or equity incentives[22] Cash and Cash Equivalents - The net increase in cash and cash equivalents was ¥104,701,963.83, representing a significant increase of 4,013.58% compared to the same period last year[19] - The total cash and cash equivalents at the end of the period rose by ¥191,404,185.45, an increase of 46.88% due to various contributing factors[19] - Cash and cash equivalents at the end of the period increased to ¥599,722,929.13 from ¥408,318,743.68, marking a rise of 46.8%[33]